Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...

Pablo Legorreta, CEO, highlighted strong 2024 performance, with Portfolio Receipts reaching $2.8 billion, at the high end of guidance and representing 13% growth in Royalty Receipts. He noted this ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & President Trump’s Sovereign Wealth Fund. In this ...

Freezing cold temperatures saw the traditionally outdoors event forced inside and held in the rotunda of the US Capitol. In his inauguration speech, Mr Trump declared "the golden age of America ...

Donald Trump is now the 47th president of the United States, as well as the 45th president, a businessman - and a man who knows how to put on a show. Former presidents, Trump family members, tech ...

The past two years have been punishing for the biotech and pharma space. As Wall Street chased the artificial-intelligence boom, drugmakers were left behind, with pharma stocks trading at a ...

NEW DELHI: India is bracing for possible disruptions to its pharmaceutical industry - where the American market accounts for almost a third of exports - during Donald Trump’s presidency.

EL PAÍS looks back at the swearing-in ceremony, which is held every four years at the Capitol in Washington Jan 20, 2025 - 12:56CET ...

Spinal Muscular Atrophy (SMA), Gaucher’s Disease, Pompe Disease, Fabry Disease, Narcissistic Personality Disorder (NPD), and Alkaptonuria, or Black Urine Disease.

Recursion Pharmaceuticals has a flashy drug development platform. It has a lot to prove about whether that platform's use of AI is helpful. Some power players have backed it with significant ...

HOUSTON and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with ...